Literature DB >> 773494

Once-daily dosing with Atenolol in patients with mild or moderate hypertension.

A P Douglas-Jones, J M Cruickshank.   

Abstract

Because of the difficulties patients have in adhering to their drug regimens a trial was performed in which patients with essential hypertension were given, in random order and for four weeks each, three different doses of atenolol to be taken once daily. Atenolol effectively decreased lying and standing blood pressures, and there was no difference between the effects of the three doses. The simplicity of the regimen, as well as atenolol's freedom from troublesome side effects, should be valuable in helping patients adhere to long-term treatment.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 773494      PMCID: PMC1639643          DOI: 10.1136/bmj.1.6016.990

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  4 in total

1.  An investigation into the cardiac and pulmonary beta-adrenoceptor blocking activity of ICI 66,082 in man.

Authors:  G E Marlin; C R Kumana; C M Kaye; D M Smith; P Turner
Journal:  Br J Clin Pharmacol       Date:  1975-04       Impact factor: 4.335

2.  Drug therapy: patient compliance.

Authors:  B Blackwell
Journal:  N Engl J Med       Date:  1973-08-02       Impact factor: 91.245

3.  Atenolol and bendrofluazide in hypertension.

Authors:  J C Petrie; D B Galloway; J Webster; W T Simpson; J A Lewis
Journal:  Br Med J       Date:  1975-10-18

4.  Initial clinical experience with I.C.I. 66.082, a new beta-adrenergic blocking agent, in hypertension.

Authors:  L Hansson; H Aberg; S Jameson; B Karlberg; R Malmcrona
Journal:  Acta Med Scand       Date:  1973-12
  4 in total
  36 in total

Review 1.  Hypertension: which beta-blocker?

Authors:  H J Waal-Manning
Journal:  Drugs       Date:  1976-12       Impact factor: 9.546

2.  Antihypertensive effect of carvedilol: a preliminary dose-response study.

Authors:  B Casadei; J Conway; A J Coats; R Bird
Journal:  Clin Investig       Date:  1992

Review 3.  Economic factors in the initiation of antihypertensive therapy.

Authors:  I Kawachi
Journal:  Pharmacoeconomics       Date:  1992-10       Impact factor: 4.981

4.  Effect of Acute and Chronic Dosing over 24 Hours.

Authors:  A M Woolfson; M S Knapp
Journal:  Proc R Soc Med       Date:  1977

5.  Placebo-controlled Multicentre Study in General Practice.

Authors:  B P Jones
Journal:  Proc R Soc Med       Date:  1977

6.  Use of fixed doses of beta blocking drugs in the treatment of hypertension. Randomised study of atenolol and penbutolol.

Authors:  L D Lameijer; L A Voermans; J J Houtzagers; D R Chadha
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

7.  Contribution of atenolol, bendrofluazide, and hydrallazine to management of severe hypertension.

Authors:  R G Wilcox; J R Mitchell
Journal:  Br Med J       Date:  1977-08-27

8.  Asthma and beta-blockers.

Authors:  D S Lawrence; J N Sahay; S S Chatterjee; J M Cruickshank
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

9.  Comparison between atenolol and nadolol in essential hypertension at rest and on exercise.

Authors:  R G Wilcox; J R Hampton
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

10.  Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs.

Authors:  N Himori; S Honma; A Izumi; T Ishimori
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-02       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.